|
Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment Clinical research trials and Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment. Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment clinical trial. Subjects frequently get the best healthcare possible for their Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment  Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment
Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment
For Condition: unspecified childhood solid tumor, protocol specific,neurotoxicity,Depression
Status: Recruiting
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute , National Cancer Institute (NCI)
Synopsis: RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may decrease depression and may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer. PURPOSE: Randomizedphase II trial to compare the effectiveness of dextroamphetamine-amphetamine with that of methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer.
Details: OBJECTIVES: - Compare the response rates in pediatric cancer patients with treatment-related neurocognitive sequelae and depression treated with dextroamphetamine-amphetamine vs methylphenidate. - Compare the durability of response at 12 weeks in patients who show a response at 3 weeks after treatment with these drugs. - Determine whether patients who have no response to one of these study drugs can respond to the other study drug. - Determine the prevalence of depression and possible response to neurostimulant therapy in this patient population. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral dextroamphetamine-amphetamine once daily for 3 weeks. Patients who achieve response (based on neurocognitive testing) continue treatment for a total of 12 weeks. Patients with no response after 3 weeks cross over to arm II after a 48-hour washout period. - Arm II: Patients receive oral methylphenidate once daily for 3 weeks. Responding patients continue treatment for a total of 12 weeks. Patients with no response after 3 weeks cross over to arm I after a 48-hour washout period. Depression and neurocognitive function are assessed at baseline, 3 weeks, and end of study. PROJECTED ACCRUAL: A total of 177 patients (approximately 88 per treatment arm) will be accrued for this study within 3 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 6 Years/17 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of a malignancy and received prior CNS treatment (e.g., surgery and/or radiotherapy and/or intrathecal chemotherapy) - Patients treated with prior systemic chemotherapy alone are not eligible - At least 6 months since prior treatment - Cancer-free for at least 6 months - Neurocognitive function at least 1 standard deviation below the level of performance predicted by patient's IQ on at least 2 of 3 WISC®-III subtests* - No diagnosis of attention deficit disorder or attention-deficit hyperactivity disorder before cancer diagnosis NOTE: *Patients who are not eligible for randomization based on test results may be retested every 3 months PATIENT CHARACTERISTICS: Age - 6 to 17 Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified Other - Estimated IQ of at least 65 (based on the WRAT-3™ reading subtest) - Not blind - No glaucoma - No family history of motor and phonic tics or Tourette's syndrome - No seizures not controlled by antiepileptic drugs - Patients not currently experiencing seizures and who have been on a stable dose of antiepileptic drugs for at least 12 weeks are eligible - Proficient in English - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics Endocrine therapy - Not specified Radiotherapy - See Disease Characteristics Surgery - See Disease Characteristics Other - No concurrent antidepressants, antipsychotics, or other stimulants - No concurrent monoamine oxidase inhibitors
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MargaretBooth-Jones, Study Chair, H. Lee Moffitt Cancer Center and Research Institute
Shands Cancer Center at the University of Florida Health Science Center *Recruiting*
Gainesville, Florida, 32610-0296
United States
Recruiting Stephen Hunger 352-392-9393
MBCCOP - South Texas Pediatrics *Recruiting*
San Antonio, Texas, 78229-3900
United States
Recruiting Anthony Infante 210-567-5265
CCOP - Scott and White Hospital *Recruiting*
Temple, Texas, 76508
United States
Recruiting Lucas Wong 254-724-7048
Tampa Children's Hospital *Recruiting*
Tampa, Florida, 33677-4227
United States
Recruiting Cameron Tebbi 813-870-4252
Children's Hospital of Southwest Florida *Recruiting*
Ft. Myers, Florida, 33908
United States
Recruiting Emad Salman 239-432-3333
CCOP - Florida Pediatric *Recruiting*
Tampa, Florida, 33682-7757
United States
Recruiting James Talbert 352-392-3718
Additional Information:
Study ID Numbers: CDR0000301614; NCI-5899,MCC-0201
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00069927
Other Depression Studies:
1. Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment
2. Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
3. Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
4. Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
5. EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
Related Studies:
Other Depression Clinical Trials
Other Florida Clinical Trials
Other Tampa Clinical Trials
Dextroamphetamine-Amphetamine Compared With Methylphenidate in Treating Children With Depression and Problems With Memory, Attention, and Thinking Caused By Cancer Treatment
|
|
|
|
|
|
|
|
